摘要
近年来,由高效的毒性药物作为"弹头"与肿瘤靶向蛋白结合形成的免疫偶联物成为靶向治疗肿瘤的研究热点。多柔比星作为经典的化疗药物,抗肿瘤机制明确,但不良反应较强,已被许多研究者用于免疫偶联物的研究中。随着偶联方式(交联剂)的不断更新,多柔比星免疫偶联物的构建方法也不断改进,对靶向治疗肿瘤的研究也取得了一定的成果。文中就多柔比星免疫偶联物构建的研究进展作一综述。
In recent years,the immunoconjugate composed of highly toxic agents and tumor-targeting proteins has become an attractive prospect for the selective delivery of cytotoxic drugs to tumors.Doxorubicin,a classic chemotherapeutic with a clear and definite mechanism but serious side effects,has been studied by many researchers in the investigation of immunoconjugates.Along with the update of the linkers,the methods for the construction of doxorubicin immunoconjugates have been improved,and advances have been made in cancer targeted therapies.
出处
《医学研究生学报》
CAS
2011年第10期87-90,共4页
Journal of Medical Postgraduates
基金
国家自然科学基金(30670599)
